| Scientist Conducted Study | Part of Curcuma Longa Plant Used |
Study Conducted on (Animal) |
Study Conducted on Human |
Trial Phase |
Models | Type of Study | Conclusion | Inference |
|---|---|---|---|---|---|---|---|---|
| Sample size | ||||||||
| Ashish Shubhas et al.(2013) [91] | Curcuminoids and oil free aqueous extract of C. longa (COFAE) |
Albino swiss Mice and Albino Wistar rats | NA | NA | Xylene induced ear edema and cotton pallet granuloma model | Comparative. | COFAE at dose level (p< 0.05) reduce inflammation in each animal model. On comparative study the oil free aqueous extract showed better anti-inflammatory effect as compared to curcuminoids. | The active constituents of curcumin has potent anti-inflammatory effect in its different forms. |
| Chang et al. (2001) [92] |
8000 mg curcumin Per day |
NA | 25 subjects | Phase I | NA | NA | The study showed that curcumin is not toxic to humans when administered for 3 months up to the dose of 8,000 mg/day (orally). | Curcumin is nontoxic to human. |
| Satoskar et al.(1986) [93] | Curcumin (1200 mg/d) and phenylbutazone (300mg/d) | NA | 45 subjects | NA | NA | Comparative Controlled trail. |
Controlled trial study was conducted (5-days) with 45 postsurgical patients divided into groups placebo, curcumin (1200 mg/d), and phenylbutazone (300 mg/d). Phenylbutazone and curcumin showed better anti-inflammatory effect. |
Curcumin showed better anti-inflammatory effect. |
| Bundy Rafe et al. (2004) [94] | 1 tablet of curcumin extract per 8th day | NA | 500 IBS (selected) 207 subjects (screened for study) |
Phase II | NA | Partially blinded, randomized, two-dose, pilot study. | The prevalence rate of inflammatory bowel syndrome found to be declined up to 41% and 57% and further the percentage declined to 53%-60% between base line after treatment in both groups. | The anti-inflammatory effect of curcumin has been seen in inflammatory bowel syndrome. |
| Chandran Binu et al. (2012) [95] |
Curcumin (500 mg) and Diclofenac Sodium (50 mg) | NA | 45 | Phase II | NA | Randomized, single-blinded, pilot study. | Patients were randomly allocated in 1:1:1 ratio for administration of curcumin 500 mg (Group I) or curcumin 500 mg + diclofenac sodium 50 mg (Group II), or diclofenac sodium 50 mg (Group III) over a period of 8 weeks. | Curcumin showed better anti-inflammatory effect and reduced pain also. |